Nucana reports third quarter 2024 financial results and provides business update

Presented encouraging phase 2 data on nuc-7738 in combination with pembrolizumab at the european society for medical oncology (esmo) congress 2024

NCNA Ratings Summary

NCNA Quant Ranking